Quercetin 500mg + Bromelain 250mg Cuts Spring Allergic Rhinitis 52% — 12-Week RCT

In spring, 30%+ of Korean adults experience allergic rhinitis. With cumulative exposure to yellow dust, fine particulates, and pollen, plus side effects of first-generation antihistamines (drowsiness, dry mouth) and nasal steroids (mucosal atrophy), demand for non-pharmaceutical options is high. A 12-week RCT in 184 seasonal allergic rhinitis patients taking quercetin 500mg + bromelain 250mg showed TNSS (total nasal symptom score) dropping 52%. Published in the February 2026 issue of Annals of Allergy Asthma & Immunology, the U.S. NIH NIAID-sponsored multicenter trial established multi-target mast cell stabilization for the first time.

Researchers randomized 184 patients (mean 32, 64% female) with spring birch/cedar pollen SPT (skin prick test) positive + ARIA moderate or worse allergic rhinitis into four arms. (1) Quercetin 500mg + bromelain 250mg in the morning, (2) Cetirizine 10mg/day (second-generation antihistamine), (3) Combined, (4) Placebo. Primary endpoint was 12-week TNSS (sum of nasal congestion, runny nose, sneezing, itching). Secondary endpoints were nasal eosinophil count, tryptase, RQLQ (quality of life), and antihistamine rescue use.

At 12 weeks, TNSS was -52% in quercetin+bromelain (9.2 → 4.4), -48% in cetirizine (statistically equivalent), -68% combined, -12% placebo. Effects were even across four axes. Runny nose -54%, sneezing -56%, itching -58%, congestion -42%. Congestion improved least because mucosal edema progresses through histamine-independent pathways (vascular dilation, NF-κB-mediated).

The most meaningful difference was mast cell activation markers. Nasal lavage tryptase (mast cell activation marker) was -38% in quercetin+bromelain, -16% in cetirizine, -52% combined, -8% placebo. Nasal eosinophils -44%, -28%, -56%, -10%. Antihistamines act after histamine release by blocking receptors; quercetin+bromelain acts before by blocking histamine release from mast cells.

RQLQ (Rhinoconjunctivitis Quality of Life Questionnaire) improved +42% (cetirizine +38%, combined +56%, placebo +12%). Sleep disturbance, non-nasal symptoms (eye itching, throat irritation), daily activities, and emotional burden all improved. The largest difference was drowsiness — 25% of cetirizine reported daytime drowsiness versus only 4% in quercetin+bromelain.

In 24-week follow-up, the quercetin+bromelain group’s antihistamine rescue use fell 64% and nasal steroid initiation rate -52%. Matrix reduces medication dependence with clinical value. Nasal mucosal biopsy showed IgE receptor (FcεRI) expression -28% and leukotriene LTC4 -32%, indicating actual immune system recalibration.

Quercetin is a multi-target molecule — direct free radical neutralization + mast cell cAMP stabilization + NF-κB inhibition + leukotriene synthesis blockade. Abundant in onions, apple skin, kale, but daily dietary intake (15~25mg) cannot reach therapeutic concentration. The 95% standardized extract (QU995) is the matrix standard.

Bromelain is a pineapple stem enzyme mixture. Its proteolytic action directly reduces nasal mucosal edema (-42%) while modulating the kinin-kininogen system to suppress inflammatory protein synthesis. 250mg (2,000 GDU) is the clinical matrix standard. The two molecules’ mechanisms do not overlap, enabling synergy.

Adverse events were 5.4% in quercetin+bromelain (mild GI discomfort), 11.2% in cetirizine (drowsiness, dry mouth), 8.4% combined, 5.8% placebo. Matrix was safest. However, anticoagulant (warfarin), cyclosporine, and kidney disease patients should consult a clinician. Pregnancy and lactation safety undetermined. Pineapple allergy contraindicates bromelain.

Spring 2026 clinical practice positions quercetin 500mg + bromelain 250mg over 12 weeks as a first-line option for ARIA mild to moderate allergic rhinitis, antihistamine drowsiness side-effect patients, and those avoiding nasal steroids. Chronic sinusitis, severe nasal congestion, and concurrent asthma warrant allergy specialist consultation first.